Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lymphoma, Follicular × tisagenlecleucel × Clear all

Phase

Phase 2 2 Phase 3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Burkitt Lymphoma 1

Interventions

Rituximab 59 Cyclophosphamide 36 Vincristine 30 Prednisone 29 Doxorubicin 24 Lenalidomide 16 Radiotherapy 15 Bendamustine Hydrochloride 13 Etoposide 9 Peripheral Blood Stem Cell Transplantation 8 Filgrastim 8 tofacitinib 7 Prednisolone 7 obinutuzumab 6 VAP-cyclo protocol 6 Deoxycholic Acid 6 ibritumomab tiuxetan 5 fludarabine 5 Mitoxantrone 5 Methylprednisolone 5 Cytarabine 5 ibrutinib 4 fludarabine phosphate 4 R-CHOP protocol 4 Melphalan 4 Dexamethasone 4 Carmustine 4 tositumomab I-131 3 Radiation 3 Methotrexate 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05888493 2026-02-20

LEDA

Novartis

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡